TB-500 (Thymosin β4 fragment)

TB-500 Half-Life and Clearance

UKPWritten & reviewed by William Heath · Editor, UK Peptides research library2 min readLast reviewed 2026-08-232 cited sources

The short answer

TB-500 carries no half-life extension technology, no fatty acid, no albumin binding, no protease-resistant substitutions beyond N-terminal acetylation. A 889 Da peptide is small enough to be filtered renally and is exposed to peptidases, so clearance is rapid.

Key facts

Size
889.0 Da. Freely filtered by the kidney
Half-life extension
None
Albumin binding
No fatty acid conjugate
N-terminal acetylation
Blocks aminopeptidases only
C-terminus
Unprotected
Endopeptidases
Unaffected by terminal capping

Two clearance routes, both open

A molecule this small passes the glomerulus unimpeded, the filtration barrier retains things around 60 kDa and above, and 889 Da is far below any threshold. Separately, peptidases in plasma and tissue cleave peptide bonds. Neither route is obstructed by anything in TB-500's structure.

What acetylation does and does not do

Aminopeptidases remove residues from a free N-terminus. Capping that terminus with an acetyl group blocks them, which is a real protective effect. It does nothing about carboxypeptidases attacking the other end, and nothing at all about endopeptidases cleaving internally. One of three routes closed is useful but not transformative.

Research material referenced

TB-500 5mg, third-party HPLC tested

Buy TB-500 · £23.99

The contrast with engineered peptides

Semaglutide illustrates what deliberate half-life extension looks like: an Aib substitution blocking DPP-4, plus a C18 diacid binding albumin so the complex is too large to filter and is physically shielded. That combination takes GLP-1 from one to two minutes to about a week. TB-500 has none of it, which is a design difference rather than an oversight. The fragment was made to study a motif, not to be a durable agent.

Why this matters for interpreting studies

A compound cleared rapidly reaches its target briefly, and effects observed in a study depend on the exposure the protocol produced. Comparing outcomes between studies using different administration schedules is comparing different exposures, not different potencies. This is the sort of detail that separates a mechanistic result from a practical one.

The full protein is different again

Thymosin beta-4 at 4,963 Da is still well below the renal filtration threshold, so it is not protected by size either, but its pharmacokinetics are not the fragment's, and studies using the protein should not be read as characterising the peptide.

Frequently asked questions

Does TB-500 have a long half-life?

No. At 889 Da with no albumin binding or protease-resistant substitutions beyond N-terminal acetylation, clearance is rapid.

What does the acetyl group protect against?

Aminopeptidases attacking the N-terminus. It does not protect the C-terminus or block internal cleavage by endopeptidases.

Why not add albumin binding like semaglutide?

The fragment was made to study a motif rather than to function as a durable agent. Half-life extension is a deliberate engineering step that was never applied here.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Browse the wider literature

Live database searches, not fixed citations. Results change as new work is indexed.

UKP

Written and reviewed by

William Heath · Editor, UK Peptides research library

William Heath edits the UK Peptides research library. He is responsible for what is published here: every article is sourced to primary literature, every purity or identity statement traces to a signed third-party certificate for a specific lot, and corrections are made in place with the review date updated. No scientific or medical credentials are claimed on this site; the evidence is carried by the cited sources and the certificates, not by the byline.

More TB-500 (Thymosin β4 fragment) articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.